Qualicaps acquires Genix Industria Farmaceutica, Brazil’s leading hard capsule manufacturer
The acquisition allows the company to effectively expand its global presence from operating sites in Japan, Spain, Romania, Canada and the US, to include Brazil.
Qualicaps has acquired Genix Industria Farmaceutica, Brazil’s leading two-piece hard capsule manufacturer with operations located in the pharmaceutical hub of Goais, and commercial activities managed from Sao Paulo.
Qualicaps is a global manufacturer of a complete assortment of two-piece hard capsules and related pharmaceutical processing equipment, belonging to Mitsubishi Chemical Holdings Corporation through The Life Sciences Institute, Inc., which encompasses its healthcare portfolio of businesses. With over a century of experience and a strong record of pioneering in new forms of drug administration, Qualicaps is responsible for several milestones in the history of hard capsule development, introducing features so widely accepted and trusted that they have since become standards in the pharmaceutical industry. The acquisition allows the company to effectively expand its global presence from operating sites in Japan, Spain, Romania, Canada and the US, to include Brazil.
Through Genix, Qualicaps will serve the pharmaceutical market in Latin America, valued by IMS Health at US$72 billion in 2014 and estimated to grow annually at an average of 5–8% through to 2019. The company will become the leading hard capsule manufacturer in the region and the only one with a production site in Brazil, the third largest pharmaceutical market in the Americas after the US and Canada, and eighth in the world. Genix currently supplies a large number of companies operating within the pharmaceutical and nutraceutical industry, and accounts for over half of Brazil’s market share in hard capsules.
In addition to a strong customer base, Genix brings to Qualicaps 13 years of experience in hard gelatin capsule manufacturing, and a robust process that is certified for Good Manufacturing Practice and Pharmaceutical Ingredients by ANVISA. From a financial perspective, consolidated figures are estimated to represent approximately a 7% growth in Qualicaps revenue in the short term, while in the long term the Americas region overall will increase in its overall contribution through planned future capacity increases. Kent M. Payne, President of Qualicaps Americas, comments to this regard: “This acquisition marks a major milestone for Qualicaps in positioning ourselves to provide a more complete coverage for our existing and potential pharmaceutical customers in the region. We look forward to continuing to accelerate our growth in Brazil and other Latin American countries as part of our overall strategic expansion plan for the Americas.”
The two companies already share an important synergy that enables their integration, as Genix has had a long-standing collaboration with Technophar, a wholly owned subsidiary of Qualicaps that provides the machinery and technology for both companies’ manufacturing processes.
“With Genix as part of the Qualicaps group of companies, we continue along the path marked by our vision of becoming the number one preferred partner to the pharmaceutical industry through addressing our customers’ needs and growth in the South American region,” comments Ciro Ahumada, Group CEO. He adds that “Genix fully complements the Qualicaps business, as it also has a strategical and operational focus on providing high-quality pharmaceutical-grade capsules along with scientific and technical support to our customers.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance